Treatment Options for Chronic Pain After Spine Surgery: A Systematic Review and Meta-Analysis of Interventional, Pharmacological, and Rehabilitative Strategies.

Persistent spinal pain syndrome type 2 (PSPS-T2), historically referred to as failed back surgery syndrome (FBSS), is a complex, debilitating chronic pain condition following spinal surgery. This nomenclature transition reflects a paradigm shift from viewing the condition as a singular surgical "failure" to a primary neuro-inflammatory and centrally sensitized disease state. While advancements in interventional techniques and neuromodulation have improved numerical pain scores, their impact on functional metrics, long-term opioid consumption, and systemic health remains heavily debated. This systematic review and network meta-analysis aim to evaluate the efficacy of current pharmacological, rehabilitative, and interventional management strategies for PSPS-T2, integrating historical functional paradigms with cutting-edge 2024-2026 neuromodulatory, investigational molecular, and massive real-world cohort evidence. Following PRISMA guidelines, a systematic search was conducted across MEDLINE, Embase, and Cochrane databases up to April 15, 2026. Screening and extraction were performed independently by two reviewers with a third-party tie-breaker. A total of 1,452 records were screened. After rigorous selection, 100 studies were included in the qualitative synthesis, and 24 randomized controlled trials (RCTs) and high-quality cohort studies were utilized for design-adjusted quantitative meta-analysis. Primary outcomes included pain intensity (using the Numerical Rating Scale (NRS) or Visual Analog Scale (VAS)) and functional disability (using the Oswestry Disability Index (ODI)). Secondary outcomes assessed long-term opioid therapy (LOT) reduction and psychological morbidity. Network meta-analysis data confirmed that spinal cord stimulation (SCS) combined with conventional medical management (CMM) is significantly superior to CMM alone (OR: 10.32, 95% CI 6.10-15.45, I2 = 68%) for achieving > 50% pain reduction. However, massive real-world cohort data encompassing 12,632 patients demonstrated that SCS implantation was not associated with a significant decrease in LOT compared to matched non-SCS cohorts (OR 1.05), establishing a critical "Opioid Paradox." Rehabilitative adjuncts, including high-intensity laser therapy (HILT) and spinal manipulative therapy (SMT), showed statistically significant improvements in ODI at 12 months. Longitudinal data further indicated a strong correlation between PSPS-T2 and an increased risk of psychiatric disorders, dementia, and all-cause mortality; these associations are likely mediated by long-term polypharmacy and physical inactivity. The management of PSPS-T2 must transition from a purely mechanical surgical model to a systemic, multidisciplinary framework. While advanced neuromodulation provides substantial pain relief in controlled environments, it fails to spontaneously resolve the long-term opioid burden in real-world populations. We conclude that successful outcomes require decoupling biological pain relief from opioid dependency behavior through early functional restoration and the integration of interventions within a holistic, biopsychosocial care pathway.